prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumB, Clinical Diagnosis & History: Invasive lobular (questionable duct), carcinoma left breast LOQ for left. wide excision with needle localization, SLNB. Specimens Submitted: 1: SP: Sentinel node #1 level one left axilla. 2: SP: Sentinel node #2 level one left axilla. 3 SP: Non-sentinel tissue left axilla. 4: SP: Sentinel node #3 level one left axilla. 5: SP: Breast, left, 4:00, excision of tumor site. 6: SP: Breast, left, superior margin. 7: SP: Breast, left, medial margin. 8: SP: Breast, left, inferior margin. 9: SP: Breast, left, lateral margin. 10: SP: Breast, left, posterior margin. DIAGNOSIS: 1. SP: Sentinel node #1 level one left axilla: Sentinel Lymph Node Status: No carcinoma present. Number of Sentinel Lymph Nodes Examined: 1. Level of Detection: Initial H&E stained section. Deeper H&E stained sections and cytokeratin AE1:AE3 stains. Extracapsular Extension: Not applicable. 2. SP: Sentinel node #2 level one left axilla: Sentinel Lymph Node Status: No carcinoma present. Number of Sentinel Lymph Nodes Examined: 1. Level of Detection: Initial HEE stained section. Deeper HEE stained sections and cytokeratin AE1:AE3 stains. Extracapsular Extension: Not applicable. 3. SP: Non-sentinel tissue left axilla: Two benign lymph nodes (0/2). 4. SP: Sentinel node #3 level one left axilla: Sentinel Lymph Node Status: No carcinoma present. Number of Sentinel Lymph Nodes Examined: 1. Level of Detection: Initial HAE stained section. Deeper HEE stained sections and cytokeratin AE1:AE3 stains. Extracapsular Extension: Not applicable. 5. SP: Breast lefti 4:00, excision of tumor site: Invasive Carcinoma: Invasive mammary carcincma (see comments). Histologic Grade: III/III: Minimal or no tubule formation 1c 10% of tumor). Nuclear Grade: III/III (marked variation in size and shape). Tumor Size: Gross measurement 26mm. Lobular Neoplasia: Lobular carcinoma in situ (LCIS), classical type. focal. Calcification: Not Identified. Lymphovascular Invasion: Not present. surgical Margins: For Final margin status see seperately submitted margins. Benign Breast Tissue: Biopsy site changes. Estrogen Receptor (6F11 , v. Positive nuclear staining in 99% of tumor cells. Strong intensity. Progesterone Receptor (182; Ventana): Positive nuclear staining in 90% of tumor cells. Strong intensity. Moderate intensity. HER2 (485,. Equivocal (2+) FISH will be performed. Membranous Staining (for Her2 positive and equivocal cases only) : 15% of invasive cells exhibit complete membranous staining. Uniformity of staining is absent. Homogenous, dark circumferential pattern is absent. Comment: This high grade invasive carcinoma has a solid growth pattern. There. is focal associated LCIS. Based on the cytomorphology and the fact. that it is E-Cadherin negative, most likely this is an invasive lobular da. with pleomorphic features. 6. SP: Breast, left, superior margin: Benign breast parenchyma. 7. SP: Breast, left, medial margin: Benign breast parenchyma and skeletal muscle. 8. SP: Breast, left, inferior margin: Benign breast parenchyma. 9. SP: Breast, left, lateral margin: Benign breast parenchyma. 10. SP: Breast, left, posterior margin: Benign breast parenchyma and skeletal muscle. Comment: Controls are satisfactory. Ventana's PATHWAY anti-HER-2/neu in an. FDA-approved rabbit monoclonal primary antibody (clone 485) directed against. the internal domain of the c-erbB-2 oncoprotein (HER2) for. imunohistochemical detection of HER2 protein overexpression in breast. cancer tissue routinely processed for histologic evaluation. Results are. reported in accordance with the ASCO/CAP guideline recommmandations for HER2. testing in breast cancer (3 Clin Oncol 2007; :118-145) ER and PR are. also rabbit monoclonal antibodies which are FDA approved. Some of the immunohistochemiatry and ISH tests were developed and their. performance characteristics were determined by the Department of Pathology. They have not been cleared or approved by the US Food and Prug. Administration. The FDA has determined that such clearance or approval. is. not necessary. These tests are used for clinical purposes. They should not. be regarded as investigational or for research. This laboratory is certified. under the Clinical Laboratory Improvement Amendments of 1988 (CLIA . 88). as. qualified to perform high complexity clinical laboratory testing. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL) AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Report slectronically Signed Out. Gross Description: 1) The specimen is received in formalin, labeled "Sentinel node #1 level 1. left axilla" and consists of a gray-tan lymph node measuring 2.2 cm in. greatest dimension. The lymph node is bisected and submitted entirely. Summary of sections: BLN - bisected lymph node. 2) The specimen is received in formalin, labeled "Sentinel node #2 level 1. left axilla" and consists of a pink-tan lymph node measuring 1.1 cm in. greatest dimansion, which is bisected and submitted entirely. Summary of sections: U undesignated. 3) The specimen is received in formalin, labeled "Non-sentinel tissue left. axilla" and consists of a piece of fatty tissue measuring 4.5 x 4.5 x 0.5 cm. in greatest dimension. A few pink-tan lymphoid nodules are identified. ranging from 0.1 to 0.7 cm in greatest dimension, which are entirely. submitted. Summary of sections: U - undesignated. 4) The specimen is received in formalin, labeled "Sentinel node #3 level 1. left axilla and consists of a pink-tan lymph node measuring 0.5 cm in. greatest dimension, which is submitted whole. Summary of sections: U undesignated. 5) The specimen is received fresh labeled "Excision of tumor site at 4. o'clock left breast. It consists of an unoriented segment of yellow-tan. fatty breast tissue measuring 8.5 x 6.5 x 3.4 cm. The specimen is received. on a cardboard grid. There is an accompanying specimen radiograph which. demonstrates a solid tumor mass containing a previous biopsy clip. The outer. surface of the specimen is inked black. In sections reveal a 2.6 x 2.4 x 2.2. cm well circumscribed, stony hard, white-tan tumor with a central previous. biopay site measuring 0.8 x 0.7 x 0.6 cm. A stereotactic biopsy clip is. identified within the biopay site. The tumor abuts the black inked tissue. edge. The remainder of the breast tissue is predominantly yellow tan fatty. and lobulated with focal white-tan fibrous areas. A sample of the tumor is. given to TPS. The remainder of the tumor is blocked out, sequentially. sectioned, and submitted entirely. Summary of sections: TB-sequential section of tumor, bisected. T-tumor. 6) The specimen is received fresh, labeled "Superior margin left breast and. consists of a piece of fibrofatty breast tissue measuring 4.3 x 3.2 cm, and. 0.9 cm thick. A stitch marks the new margin of excision, which is inked. black. No tumor is grosaly identified. The tissue is serially sectioned and. entirely submitted. Summary of sections: ss - sequential sections. 7) The specimen is received fresh, labeled "Medial margin left breast and. consists of a piece of fibrofatty breast tissue measuring 3.8 x 3.2, and 1.0. cm thick. A stitch marks the new margin of excision, which is inked black. No tumor is grossly identified. The tissue is serially sectioned and. entirely submitted. Summary of sections: SS - sequential sections. 8) The specimen is received fresh, labeled "Inferior margin left breast and. consists of a piece of fibrofatty breast tissue measuring 4.0 x 3.9, and 1.5. cm thick. A stitch marks the new margin of excision, which is inked black. No tumor is grossly identified. The tiasue is serially sectioned and. entirely submitted. Summary of sections: ss - sequential sections. 9) The specimen is received fresh, labeled Lateral margin left breast" and. consists of a piece of fibrofatty breast tissue measuring 4.9 x 3.5cm and. 1.2 cm thick. A stitch marks the new margin of excision, which is inked. black. No tumor is grossly identified. The tissue is serially sectioned and. entirely submitted. Summary of sections: SS - sequential sections. 10) The specimen is received fresh, labeled "Posterior margin left breast. and consists of a piece of fibrofatty breast tissue measuring 4.7 x 2.5 cm. and 0.5 cm thick. A stitch marks the new margin of excision, which is inked. black. No tumor is grossly identified. The tissue is serially sectioned and. entirely submitted. Summary of sections: ss - sequential sections. Summary of Sections: Part 1: SP: Sentinel node #1 level one left axilla. Block. Sect. Site. PCs. 1. bln. 1. Part 2: SP: Sentinel node #2 level one left axilla. Block. Sect. Site. PCs. 1. bln. 1. Part 3: SP: Non-sentinel tissue left axilla. Block. Sect. Site. PCs. 1. u. Part 4: SP: Sentinel node #3 level one left axilla. Block. Sect. Site. PCs. 1. Part 5: SP: Breast, left, 4:00, excision of tumor site. Block. Sect. Site. PCs. 1. T. 1. 2. TA. 2. 2. TB. 2. 2. TC. 2. Part 6: SP: Breast, left, superior margin. Block. Sect. Site. PCs. 6. as. 6. Part 7: SP: Breast, left, medial margin. Block. Sect. Site. PCs. 5. ss. 5. Part 8: SP: Breast, left, inferior margin. Block. Sect. Site. PCs. 6. ss. 6. Part 9: SP: Breast, left, lateral margin. Block. Sect. Site. PCs. 5. ss. 5. Part 10: SP: Breast, left, posterior margin. Block. Sect. Site. PCs. 5. ss. 5. Procedures/AAdenda: Addendum. Date Complete. Addendum Diagnosis. PART #5: LEFT BREAST. ONCOTYPE TESTING RESULTS RECEIVED ON. :CURRENCE SCORK -23. AVERAGE RATE OF DISTANT RECURRENCE OF 15% (95% CI: 12%-18%). TESTING WAS PERFORMED AT: ONCOTYPE REPORT CAN BE FOUND IN. Specimens Submitted: 1: LEFT BREAST 4:00. Test Performed: FISA for detection of gene amplification. Methodology: Fluorescence in situ Hybridization (FISH) is performed using FDA-approved. ERBB2 (HER2/NEU) PathVysion assay probes and procedure. DIAGNOSTIC INTERPRETATION: HER2/ CEP 17. 1.01 NOT AMPLIFIED. Her-2/neu gene amplification is NOT detected. (cut off ratio: > 2.2 HER2 gene amplified; < 1.8 HER2 gene not amplified;. 1.8 2.2 equivocal). LAB) NOTES: Block # 5 (TA1). Specimen fixative type: Formalin. Adequate number of invasive tumor cells present: Yes. Number of invasive tumor cells counted: 20 + 20. Average number of HER2 probe signals per nucleus: 3.2. Average number of CEP17 chromosome probe signals per nucleus: 3.2. Average HER2/CEP 17 ratio: 1.0. The PathVysion HER2 DNA probe kit (Vysis) is an FDA-approved method. for assessment of HER2 gene amplification in breast cancer specimens. The. HER2 test results are reported in accordance with the ASCO/CAP guideline. reccmmendations for HER2 testing in breast cancer (J Clin Oncol 2007; 25. (1):118-145). I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIENED AND APPROVED. THIS REPORT.

expanded version (tokens=3321) : 
 Main points from the breast pathology report:

1. Histological classification: Invasive mammary carcinoma (subtype LumB) and lobular carcinoma in situ (LCIS, classical type).
2. Necrosis: No mention of necrosis.
3. Tumor infiltrating lymphocytes: No mention of tumor infiltrating lymphocytes.
4. Histological grade: Grade III/III, with minimal or no tubule formation and marked variation in size and shape of the nuclear grade.
5. Lymphovascular invasion: Not present.
6. Calcification: Not identified.
7. Receptor status: Estrogen receptor (ER) positive in 99% of tumor cells with strong intensity, progesterone receptor (PR) positive in 90% of tumor cells with moderate intensity. HER2 status is equivocal (2+), further testing with fluorescence in situ hybridization (FISH) will be performed.
8. Other ancillary testing results: Oncotype testing results indicate an average rate of distant recurrence of 15%. FISH testing for HER2 gene amplification shows that the HER2 gene is not amplified (HER2/CEP17 ratio: 1.0).

Overall, the diagnosis suggests a high-grade invasive carcinoma with a solid growth pattern, possibly invasive lobular carcinoma with pleomorphic features.

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=3471) : 
 Diagnosis: Invasive mammary carcinoma (LumB) with grade III/III histological features. No necrosis, lymphovascular invasion, or calcification observed. ER-positive in 99% of tumor cells, PR-positive in 90% of tumor cells. HER2 status equivocal, further testing required. Oncotype testing indicates a 15% average rate of distant recurrence. FISH analysis shows no amplification of HER2 gene. Possible diagnosis of invasive lobular carcinoma with pleomorphic features.

